文献速递心境障碍

氯胺酮减轻LPS诱导抑郁样小鼠模型中的微胶质激活和脑单核细胞浸润并促进外周调节性免疫细胞

Ketamine reduces microglial activation and brain monocyte infiltration and promotes peripheral regulatory immune cells, relieving lipopolysaccharide (LPS)-induced depressive-like behavior in mice.
PubMed 文献 · Mol Psychiatry · 2025-11-18

该研究在脂多糖(LPS)诱导的抑郁样小鼠模型中探究氯胺酮的抗抑郁与抗炎作用。氯胺酮(10-20 mg/kg)改善了悬尾实验和糖水偏好实验中的绝望与快感缺失,并减少脑内Ly6Chigh单核细胞浸润和微胶质激活,同时促进外周调节性免疫细胞。用MK-801和雷帕霉素进一步表明抗炎与抗抑郁效应相关联。

要点

  • 氯胺酮(10-20 mg/kg)改善LPS抑郁样小鼠的绝望和快感缺失行为。
  • 氯胺酮减少脑内Ly6Chigh单核细胞浸润并抑制微胶质激活。
  • 氯胺酮促进外周调节性免疫细胞和M2型巨噬细胞极化。

核心结论

  • 氯胺酮在LPS诱导的抑郁样小鼠中具有抗抑郁和抗炎作用,且两者可能相关联。

研究设计与样本

  • 研究采用LPS诱导的抑郁样小鼠模型,通过悬尾实验和糖水偏好实验评估行为,并用流式细胞术分析血液、脾和脑的免疫表型。

主要发现

  • 氯胺酮(10-20 mg/kg)减轻LPS抑郁样小鼠的绝望和快感缺失。
  • 氯胺酮降低血中Ly6G+中性粒细胞并增加抗炎性Ly6Clow/neg单核细胞。
  • 氯胺酮减少CD45highLy6GnegLy6Chigh单核细胞向脑内浸润并抑制微胶质激活(CD45lowCD11bhigh)。
  • 氯胺酮减少脾脏中LPS诱导的急性T淋巴细胞反应(CD3+CD4negCD8neg)扩增,增加CD4+CD69+TIM-3+调节性淋巴细胞比例。
  • 氯胺酮使脾巨噬细胞向抗炎CD206+M2表型极化。

临床怎么用

  • 氯胺酮可能尤其适用于伴有显著炎症的抑郁症患者,但需进一步临床验证。

局限性

  • 研究为小鼠模型,结论外推至人类需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ketamine has emerged as a rapid and sustained treatment for Major Depressive Disorder (MDD) and an alternative for patients who have not responded to traditional therapies. Its effects have been partly attributed to the noncompetitive antagonism of the N-methyl-D-aspartate receptor (NMDAR) in the central nervous system, which enhances neuroplasticity. However, the etiopathology of MDD is complex, and substantial evidence suggests that inflammation may significantly contribute to the initiation and maintenance of MDD. Furthermore, the rapid and sustained antidepressant effect of ketamine may be attributed to its anti-inflammatory and immunomodulatory actions. To investigate the antidepressant and anti-inflammatory effect of ketamine, we used a lipopolysaccharide (LPS)-induced depressive-like murine model. The Tail Suspension Test (TST) and Sucrose Preference Test (SPT) were conducted to assess depressive-like behaviors. Additionally, cellular immunophenotyping of blood, spleen, and brain was performed by flow cytometry. Ketamine administration (10-20 mg/kg) alleviated despair and anhedonia in LPS-depressive-like mice, as evidenced by the TST and SPT tests. Behavioral changes were accompanied by the reduction of Ly6G+ neutrophils and an increment of anti-inflammatory Ly6Clow/neg monocytes in the blood. Ketamine treatment also reduced CD45highLy6GnegLy6Chigh monocyte infiltration into the brain and dampened microglial activation (CD45lowCD11bhigh). In the spleen, ketamine decreased the expansion of acute T lymphocyte response (CD3+CD4negCD8neg) induced by LPS, while increasing the percentage of CD4+CD69+TIM-3+ lymphocytes, known for their regulatory function. Splenic macrophages were also polarized towards an anti-inflammatory CD206+M2-phenotype with ketamine. Finally, we showed that the anti-inflammatory and antidepressant effects are linked, perhaps as convergent outcomes, by using another NMDA receptor antagonist, MK-801, and the mTOR signaling inhibitor, rapamycin. These findings highlight ketamine's multifaceted mechanisms of action, underscoring its potential as a treatment for MDD, particularly in patients with significant inflammation.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Arena AR, Rubinstein MR, Genaro AM, et al. Ketamine reduces microglial activation and brain monocyte infiltration and promotes peripheral regulatory immune cells, relieving lipopolysaccharide (LPS)-induced depressive-like behavior in mice. Mol Psychiatry. 2025. PMID: 41254322. doi:10.1038/s41380-025-03338-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。